Literature DB >> 9285589

A second endogenous cannabinoid that modulates long-term potentiation.

N Stella1, P Schweitzer, D Piomelli.   

Abstract

Cannabinoid receptors are molecular targets for marijuana and hashish, the widespread drugs of abuse. These receptors are expressed in areas of the central nervous system that contribute in important ways to the control of memory, cognition, movement and pain perception. Indeed, such functions can be strongly influenced by cannabinoid drugs, with consequences that include euphoria, analgesia, sedation and memory impairment. Although the pharmacology of cannabinoid drugs is now beginning to be understood, we still lack essential information on the endogenous signalling system(s) by which cannabinoid receptors are normally engaged. An endogenous ligand for cannabinoid receptors, anandamide, has been described. Here we report that sn-2 arachidonylglycerol (2-AG), a cannabinoid ligand isolated from intestinal tissue, is present in brain in amounts 170 times greater than anandamide. 2-AG is produced in hippocampal slices by stimulation of the Schaffer collaterals, an excitatory fibre tract that projects from CA3 to CA1 neurons. Formation of 2-AG is calcium dependent and is mediated by the enzymes phospholipase C and diacylglycerol lipase. 2-AG activates neuronal cannabinoid receptors as a full agonist, and prevents the induction of long-term potentiation at CA3-CA1 synapses. Our results indicate that 2-AG is a second endogenous cannabinoid ligand in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285589     DOI: 10.1038/42015

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  414 in total

1.  N-Acylethanolamines in seeds. Quantification Of molecular species and their degradation upon imbibition

Authors: 
Journal:  Plant Physiol       Date:  1999-08       Impact factor: 8.340

2.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

Review 3.  How might cannabinoids influence sexual behavior?

Authors:  N Stella
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

4.  Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration.

Authors:  J Nie; D L Lewis
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

5.  Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons.

Authors:  I Katona; B Sperlágh; A Sík; A Käfalvi; E S Vizi; K Mackie; T F Freund
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

6.  Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets.

Authors:  A Berger; G Crozier; T Bisogno; P Cavaliere; S Innis; V Di Marzo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

7.  Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Authors:  Stephen A Varvel; Laura E Wise; Aron H Lichtman
Journal:  Drug Dev Res       Date:  2009-12-01       Impact factor: 4.360

Review 8.  Lipidomic analysis of endocannabinoid metabolism in biological samples.

Authors:  Giuseppe Astarita; Daniele Piomelli
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-01-14       Impact factor: 3.205

9.  The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons.

Authors:  Silvia Marinelli; Simone Pacioni; Tiziana Bisogno; Vincenzo Di Marzo; David A Prince; John R Huguenard; Alberto Bacci
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

10.  A novel GPR55-mediated satiety signal in the oval Bed Nucleus of the Stria Terminalis.

Authors:  E R Hawken; C P Normandeau; J Gardner Gregory; B Cécyre; J-F Bouchard; K Mackie; É C Dumont
Journal:  Neuropsychopharmacology       Date:  2019-01-07       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.